Vertex Pharmaceuticals Incorporated

NasdaqGS:VRTX Stock Report

Market Cap: US$128.7b

Vertex Pharmaceuticals Management

Management criteria checks 2/4

Vertex Pharmaceuticals' CEO is Reshma Kewalramani, appointed in Apr 2020, has a tenure of 4.58 years. total yearly compensation is $20.59M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 0.035% of the company’s shares, worth $45.38M. The average tenure of the management team and the board of directors is 5.1 years and 4.8 years respectively.

Key information

Reshma Kewalramani

Chief executive officer

US$20.6m

Total compensation

CEO salary percentage7.3%
CEO tenure4.6yrs
CEO ownership0.04%
Management average tenure5.1yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It

Nov 05

Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride

Oct 18

Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)

Oct 10

Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug

Sep 15

Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced

Sep 05

Vertex Stock: Came For CF Drugs, Staying For Gene Therapy

Aug 02

Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Jul 11
Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management

Jul 09

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Jun 20
If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales

Jun 17

Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time

Jun 04

Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

May 09
Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 08
Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Apr 11

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Apr 05
Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Mar 21

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Mar 15
Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Feb 28

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Feb 22
We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07
Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Jan 22

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Jan 15
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dec 25
Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Nov 13
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Oct 02
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jul 31
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Jul 03
We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

CEO Compensation Analysis

How has Reshma Kewalramani's remuneration changed compared to Vertex Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$480m

Jun 30 2024n/an/a

-US$490m

Mar 31 2024n/an/a

US$4b

Dec 31 2023US$21mUS$2m

US$4b

Sep 30 2023n/an/a

US$3b

Jun 30 2023n/an/a

US$3b

Mar 31 2023n/an/a

US$3b

Dec 31 2022US$16mUS$1m

US$3b

Sep 30 2022n/an/a

US$3b

Jun 30 2022n/an/a

US$3b

Mar 31 2022n/an/a

US$2b

Dec 31 2021US$15mUS$1m

US$2b

Sep 30 2021n/an/a

US$2b

Jun 30 2021n/an/a

US$2b

Mar 31 2021n/an/a

US$3b

Dec 31 2020US$9mUS$1m

US$3b

Sep 30 2020n/an/a

US$3b

Jun 30 2020n/an/a

US$2b

Mar 31 2020n/an/a

US$2b

Dec 31 2019US$7mUS$702k

US$1b

Compensation vs Market: Reshma's total compensation ($USD20.59M) is above average for companies of similar size in the US market ($USD12.86M).

Compensation vs Earnings: Reshma's compensation has increased whilst the company is unprofitable.


CEO

Reshma Kewalramani (51 yo)

4.6yrs

Tenure

US$20,594,441

Compensation

Dr. Reshma Kewalramani, M.D., FASN, is Director at Year Up Inc. since September 2023. She had been an Independent Director of Ginkgo Bioworks Holdings, Inc. (formerly known as Ginkgo Bioworks, Inc.) since...


Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Leiden
Executive Chairman15.3yrsUS$6.60m0.0040%
$ 5.2m
Reshma Kewalramani
CEO, President & Director4.6yrsUS$20.59m0.035%
$ 45.4m
Charles Wagner
Executive VP & CFO5.6yrsUS$7.37m0.018%
$ 23.5m
Stuart Arbuckle
Executive VP & COO3.3yrsUS$9.00m0.019%
$ 24.9m
David Altshuler
Executive VP & Chief Scientific Officer9.8yrsUS$6.54m0.010%
$ 12.9m
Kristen Ambrose
Senior VP & Chief Accounting Officer3.5yrsno data0.0029%
$ 3.7m
Mike Tirozzi
SVP and Chief Information & Data Officer5.8yrsno datano data
Susie Lisa
Senior Vice President of Investor Relations2.2yrsno datano data
Jonathan Biller
Executive VP & Chief Legal Officer2.2yrsno data0.0065%
$ 8.3m
Nina Devlin
Senior VP & Chief Communications Officer5.8yrsno datano data
Stephanie Franklin
Senior VP & Chief Human Resources Officer7.3yrsno datano data
Amit Sachdev
Executive VP & Chief Patient and External Affairs Officer17.3yrsUS$6.20m0.023%
$ 29.0m

5.1yrs

Average Tenure

57yo

Average Age

Experienced Management: VRTX's management team is seasoned and experienced (5.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jeffrey Leiden
Executive Chairman15.3yrsUS$6.60m0.0040%
$ 5.2m
Reshma Kewalramani
CEO, President & Director4.8yrsUS$20.59m0.035%
$ 45.4m
Bruce Sachs
Lead Independent Director26.8yrsUS$600.04k0.015%
$ 20.0m
Alan Garber
Independent Director7.4yrsUS$537.63k0.0023%
$ 2.9m
Lloyd Carney
Independent Director5.8yrsUS$559.79k0.0021%
$ 2.7m
Sangeeta Bhatia
Independent Director9.4yrsUS$550.31k0.0013%
$ 1.7m
Michel Lagarde
Independent Director1.1yrsUS$449.08kno data
Diana McKenzie
Independent Director4.4yrsUS$553.11k0.00064%
$ 823.9k
Suketu Upadhyay
Independent Director2.5yrsUS$544.66k0.00060%
$ 772.4k
Nancy Thornberry
Independent Directorless than a yearUS$407.65kno data
Jennifer Schneider
Independent Directorless than a yearno datano data

4.8yrs

Average Tenure

59yo

Average Age

Experienced Board: VRTX's board of directors are considered experienced (4.8 years average tenure).